OncoCyte announces VitaGraft data published in journal

Oncocyte (OCX) announced additional data regarding its lead assay VitaGraft, which was published in the journal, Nephrology Dialysis Transplantation. VitaGraft Kidney(TM) quantifies the amount of DNA fragments in transplant patients’ blood that originate from the donor organ, a key biomarker for assessing graft health. This process is commonly referred to as donor-derived cell-free DNA testing and is widely used in clinical practice. In this latest study, Oncocyte’s proprietary diagnostic dd-cfDNA test using digital PCR was able to diagnose antibody-mediated rejection in kidney transplant recipients nearly a year ahead of standard protocols. Oncocyte expects to submit for claims expansion to its payor, MolDX2, to support the use of VitaGraft for these high-risk patients in the clinic. If granted, it would expand the use case beyond the current for-cause claim, opening new revenue opportunities.